AML
Showing 26 - 50 of 149
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Canada, United States (CFI-400945, Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +5 more
- CFI-400945
- +2 more
-
Duarte, California
- +7 more
Jul 20, 2022
AML Trial in Hangzhou (CLL1+CD33 CAR-T)
Not yet recruiting
- AML
- CLL1+CD33 CAR-T
-
Hangzhou, ChinaMingming Zhang Zhang
Jul 19, 2022
AML Trial in Hangzhou (CLL1 CAR-T)
Not yet recruiting
- AML
- CLL1 CAR-T
-
Hangzhou, ChinaThe First Affiliated Hospital, Zhejiang University
Jul 17, 2022
AML Trial in Hangzhou (ADGRE2 CAR-T)
Not yet recruiting
- AML
- ADGRE2 CAR-T
-
Hangzhou, ChinaMingming Zhang Zhang
Jul 17, 2022
Defining Clinical Potential of Mass Response asBiomarker for
Recruiting
- Stage III Breast Cancer
- +5 more
-
Columbus, GeorgiaColumbus Regional Research Institute, John B. Amos Cancer Center
Jul 13, 2022
AML, Acute Myeloid Leukemia Trial in Charlottesville (Cardioprotection)
Recruiting
- AML
- Acute Myeloid Leukemia
-
Charlottesville, VirginiaUniversity of Virginia
Jul 2, 2022
Acute Myeloid Leukemia, AML, AML, Adult Recurrent Trial (flotetuzumab)
No longer available
- Acute Myeloid Leukemia
- +2 more
- flotetuzumab
- (no location specified)
May 24, 2022
AML Trial in Wuhan (CAR--?dT cells)
Recruiting
- AML
- CAR--γδT cells
-
Wuhan, Hubei, ChinaTongji Hospital
May 24, 2022
AML, B-ALL, T-ALL Trial in Memphis (CD123-CAR T, Cyclophosphamide, Fludarabine)
Recruiting
- AML
- +4 more
- CD123-CAR T
- +4 more
-
Memphis, Tennessee
- +1 more
May 10, 2022
AML, ALL, MDS Trial in New York (Clofarabine, Fludarabine, Busulfan)
Recruiting
- AML
- +8 more
- Clofarabine
- +5 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 13, 2022
Familial Investigations of Childhood Cancer Predisposition
Recruiting
- Acute Leukemia
- +45 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
May 11, 2022
AML Trial in Moscow (allo-HSCT)
Recruiting
- AML
- allo-HSCT
-
Moscow, Russian FederationNational Research Center for Hematology
Apr 14, 2022
AML Trial in Worldwide (Flotetuzumab dose escalation, Flotetuzumab dose expansion, Ruxolitinib)
Active, not recruiting
- AML
- Flotetuzumab dose escalation
- +2 more
-
Duarte, California
- +42 more
Mar 7, 2022
AML Trial in Puerto Rico, United States (Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only))
Completed
- AML
- Cytarabine (Phase 1 only)
- +3 more
-
Los Angeles, California
- +16 more
Feb 22, 2022
AML, MDS Trial in Tianjin (SHR-1702)
Active, not recruiting
- AML
- MDS
-
Tianjin, Tianjin, ChinaBlood disease hospital of Chinese Academy of Medical Sciences
Mar 7, 2022
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute Trial in Canada, United States (Iomab-B, Conventional
Active, not recruiting
- Acute Myeloid Leukemia
- +8 more
- Iomab-B
- +2 more
-
Gilbert, Arizona
- +23 more
Feb 22, 2022
AML Trial in Hangzhou (CLL1 CAR T-cells)
Recruiting
- AML
- CLL1 CAR T-cells
-
Hangzhou, Zhejiang, China
- +1 more
Feb 13, 2022
AML Trial in Hangzhou (CD38 CAR T-cells)
Recruiting
- AML
- CD38 CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Feb 13, 2022
AML, MDS Trial in United States (APVO436)
Recruiting
- AML
- MDS
- APVO436
-
San Francisco, California
- +11 more
Feb 8, 2022